Results 61 to 70 of about 11,492 (188)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients

open access: yesIndian Dermatology Online Journal, 2016
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines.
Kiran Godse   +9 more
doaj   +1 more source

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

open access: yes, 2019
Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de ...
Alarcón de la Lastra Romero, Catalina   +4 more
core   +3 more sources

OMALIZUMAB: EXPANDED OPPORTUNITIES FOR THE ATOPIC DISEASES TREATMENT

open access: yesПедиатрическая фармакология, 2009
The review highlights experience and administration perspectives of the immunobiological medication Omalizumab in allergy. Omalizumab is the anti'IgE monoclonal antibody.
T.V. Kulichenko
doaj   +2 more sources

Asthma and Therapeutics: Recombinant Therapies in Asthma [PDF]

open access: yes, 2005
Numerous recombinant therapies are being investigated for the treatment of asthma. This report reviews the current status of several of these novel agents.
Donald W Cockcroft
core   +2 more sources

Revisiting Nasal Polyp Scoring in Clinical Trials: Interpretive Variability and the Need for Standardization

open access: yes
International Forum of Allergy &Rhinology, EarlyView.
Leigh J. Sowerby   +4 more
wiley   +1 more source

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry

open access: yesAllergy, EarlyView.
Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir   +25 more
wiley   +1 more source

Omalizumab for management of refractory urticaria: Experience of a tertiary care centre in Eastern India

open access: yesIndian Journal of Dermatology, 2018
Aim: To study the effects of omalizumab in chronic spontaneous urticaria in Indian patients. Setting and Design: The study was conducted in a tertiary care centre and it was retrospective and descriptive in nature.
Shekhar Neema, Manas Chatterjee
doaj   +1 more source

Krooniline urtikaaria [PDF]

open access: yes, 2017
Krooniline urtikaaria on nahahaigus, mida iseloomustab kuplade esinemine nahal 6 nädala vältel või kauem. Enamikul juhtudel allub see hästi ravile uue põlvkonna H1-antihistamiinikumidega, kuid teatud juhtudel on vaja kasutada veel põletikuvastase või ...
Kaldvee, Bret, Karelson, Maire
core   +2 more sources

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

open access: yesAllergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier   +221 more
wiley   +1 more source

Bronchial thermoplasty : a new therapeutic option for the treatment of severe, uncontrolled asthma in adults [PDF]

open access: yes, 2014
Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment.
Alagha, Khuder   +10 more
core   +5 more sources

Home - About - Disclaimer - Privacy